Breast cancer remains one of the most common cancers affecting women globally, with late detection frequently contributing to its high mortality rate. Multiple factors drive these delays, including a lack of awareness, financial constraints in low-income countries, and limited access to non-invasive and accurate biomarkers. This review aims to introduce biomarkers, particularly hematological and biochemical serum markers, as essential, non-invasive, and accurate tools for improving the diagnosis, prognosis, and therapeutic management of breast cancer. Hematological markers are measurable blood parameters that reflect physiological and pathological processes such as inflammation, infection, cardiovascular stress, autoimmune conditions, and cancer. Routinely measured hematological markers, such as the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and red blood cell indices, are typically obtained from standard tests like the complete blood count. Regular monitoring through complete blood count is essential during cancer treatment to evaluate changes in blood cell counts and detect potential adverse effects. Because of their affordability, minimal infrastructure requirements, and broad accessibility, hematological parameters have been increasingly studied for their association with high-risk factors in breast cancer, particularly in resource-limited settings. Their utility underscores their critical role in improving patient outcomes across diverse healthcare environments. This review summarizes the clinical value of various hematological and serum-based biochemical markers in the screening and diagnosis of breast cancer. Prediction methods that incorporate hematological and serum-based biochemical parameters can support screening, diagnosis, and staging. Overall, individual or combined blood indicators hold significant potential to enhance diagnostic accuracy and effectiveness.

When gene transcription falls out of sync with other biological processes, that dysfunction can contribute to aging, cancer and other diseases. Researchers revealed how key regulatory proteins work in a precise hierarchy to meticulously adjust pacing during transcription. These regulatory proteins may now emerge as potential drug targets for a variety of disorders. The single-molecule platform that revealed these findings is a novel approach to studying similar processes that could have broad applications in biology.

Study of 48,000 AYAs finds nearly 1 in 10 develop metastatic recurrence after non-metastatic cancer, highlighting urgent need for tailored survivorship care and early detection strategies.

For some patients with the most common type of lung cancer, known as lung adenocarcinoma, there's new hope. In a new study published in Cell Reports, Mayo Clinic researchers have found several previously unknown genetic and cellular processes that occur in lung adenocarcinoma tumors that respond well to immunotherapy.

The findings from this cohort study highlight the overall burden of metastatic disease in adolescents and young adults, expanding the knowledge of metastatic recurrences that help improve care for adolescent and young adult survivors throughout the cancer survivorship spectrum. 

The monetary consequences of National Cancer Institute recissions is substantial despite the limited relevance of cancer research to ideological controversies. Disrupted grants affected most states and many public and private institutions. Many grant terminations affected research trainees and junior faculty, suggesting that these terminations not only interrupted the continuity of research studies, but also jeopardized career trajectories of early-stage investigators, with potential downstream consequences on the research workforce and innovation pipeline.